Janssen Vaccines & Prevention, a Johnson & Johnson unit, along with a consortium...
Roche’s Tecentriq combination passes Phase III melanoma study
Roche has said that the Phase III IMspire150 clinical trial of Tecentriq (atezolizumab) plus Cotellic (cobimetinib) and Zelboraf (vemurafenib) met its primary endpoint in treatment-naive patients with BRAF V600 mutation-positive advanced melanoma.
Merck reports additional positive data for Keytruda in NSCLC
Merck (MSD) has reported that an exploratory analysis of the Phase III KEYNOTE-042 clinical trial revealed improvements with Keytruda in people suffering from metastatic non-squamous non-small cell lung cancer (NSCLC).
Sangamo’s gene therapy shows promise in beta thalassemia study
Preliminary results from Sangamo Therapeutics’ Phase I/II THALES clinical trial of ST-400 have demonstrated a favourable profile of the gene therapy in treating transfusion-dependent beta thalassemia (TDT) patients.
Biohaven to continue testing troriluzole in Alzheimer’s patients
Biohaven Pharmaceutical has received notification from the independent Data Safety Monitoring Board (DSMB) to continue its Phase II/III T2 Protect AD study of troriluzole for the treatment of mild-to-moderate Alzheimer's disease.
Ipsen places hold on paediatric patients in palovarotene’s studies
Ipsen has placed a partial clinical hold on all global sites of the Phase II PVO-1A-202/204, PVO-2A-201, and Phase III PVO-1A-301 clinical trials assessing palovarotene.
November’s top news stories
Eli Lilly and Boehringer Ingelheim started a Phase III clinical trial, EMPULSE, to evaluate whether Jardiance (empagliflozin) improves acute heart failure, and The Janssen Pharmaceutical Companies of Johnson & Johnson is reimagining digital clinical trial design with the launch of a new study. Clinicaltrialsarena.com wraps up key headlines from November 2019.
Sage Therapeutics’ SAGE-217 fails in late-stage depression trial
Top-line data from Sage Therapeutics’ Phase III MOUNTAIN clinical trial have shown that SAGE-217 failed to meet the primary endpoint in adults with major depressive disorder (MDD).
Acadia’s drug cuts psychosis relapse risk in dementia patients
Acadia Pharmaceuticals has reported that pimavanserin reduced the risk of psychosis relapse in dementia patients who participated in its Phase III HARMONY clinical trial.
AstraZeneca’s olaparib shows promise in Phase II prostate cancer trial
A Phase II clinical trial led by The Institute of Cancer Research (ICR) in London and The Royal Marsden NHS Foundation Trust has shown that AstraZeneca’s olaparib could improve survival rates in prostate cancer patients.